Margarida Espadinha graduated in Applied Chemistry (Organic Chemistry field) in 2013 from the Faculty of Sciences and Technology of the New University of Lisbon and, in 2015, obtained her MSc degree in Bioorganic Chemistry at the same University. After a short stay at the Institute of chemistry CNRS (Nice, France), under a STSM-CM1106 supported by the Cost Action, she started a research grant funded by pharmaceutical company Hovione in colaboration with Santos’ group at the Faculty of Pharmacy of University of Lisbon. In October 2021, she completed a PhD in Pharmacy at the Faculty of Pharmacy of University of Lisbon. During her PhD, she worked on the development of novel p53 activators by targeting p53 protein-protein interactions as an anticancer approach, under the supervision of Prof. Maria M. M. Santos, Prof. Stuart J. Conway and Prof. Cecília Rodrigues. As part of her PhD project, she spent 6 months in the Conway Lab at the University of Oxford, UK, where she worked on the targeted protein degradation field. In November 2021, she joined the Medicinal Chemistry group at the University of Antwerp, in Belgium, as Postdoctoral Research Fellow. The current focus of her work is to investigate and develop selective serine dipeptidyl peptidase inhibitors and bivalent chemical degraders for cancer therapy, under the supervision of Prof. Pieter Van Der Veken.